Share This Page:   

 

Browse by Clinical Topic:
Select a Topic to Learn More

Featured CME/CE Content:

 

neuroscienceCME Editors' Picks:

Schizophrenia and Approaches to Recovery

neuroscienceCME Multimedia Snack

Premiere Date: Thursday, December 13, 2012

This activity offers CE credit for:

1. Physicians (CME)
2. Pharmacists (ACPE)
3. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Friday, December 13, 2013
Note: Credit Is No Longer Available

Faculty

S. Charles Schulz, MD  Professor and Head Donald W. Hastings Endowed Chair Department of Psychiatry University of Minnesota Medical School Minneapolis, MN

John Lauriello, MD  Daniel Lieberman Professor and Chair Department of Psychiatry and Human Behavior Senior Vice President of Behavioral Health Sidney Kimmel Medical College at Thomas Jefferson University Philadelphia, PA

Statement of Need

The Remission in Schizophrenia Working Group (RSWG) published operationalized criteria for symptomatic remission for schizophrenia in 2005. These criteria have been extensively applied in research settings and have stimulated research into other components of outcomes, particularly functional outcome and quality of life.(1) Attention has also shifted beyond remission to the more complex and difficult-to-attain concept of recovery. Treating patients to remission and recovery is a new goal of clinical work in schizophrenia and includes improved measures of social and occupational functional outcomes, quality of life, and cognitive status.(2)

This neuroscienceCME Snack™ describes the challenges of treating patients with schizophrenia and working as a partner with patients toward a goal of response, remission, and recovery…the 3 Rs of schizophrenia treatment.

---

1. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162(3):441-449. PMID: 15741458.
2. Emsley R, Chiliza B, Asmal L, Lehloenya K. The concepts of remission and recovery in schizophrenia. Curr Opin Psychiatry. 2011;24(2):114-121. PMID: 21285703.

Activity Goal

Improve clinicians approach to treating patients with schizophrenia to include a target goal of the 3 Rs of Response, Remission and Recovery.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Implement a treatment program that has recovery as a treatment goal for patients with schizophrenia … a recovery that involves a stepwise progression from response to remission, and then to recovery.

Financial Support

This activity is supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.

Target Audience

Physicians, pharmacists and other health care professionals who manage patients with a diagnosis of schizophrenia.

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .5 contact hours (0.05 CEUs)
Universal Activity Number: 0376-0000-12-035-H01-P (recorded programs)
Activity Type: knowledge-based

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (80% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Schulz has disclosed that he received grant support from AstraZeneca Pharmaceutical LP; Otsuka America Pharmaceutical, Inc.; and Myriad Genetics Inc./Rules-Based Medicine, Inc. He serves as a consultant for Lilly USA, LLC..

Dr. Lauriello has disclosed that he receives grants/research support from Sunovion Pharmaceuticals, Inc. He serves as a consultant to Otsuka America Pharmaceutical, Inc. and Ortho-McNeil Pharmaceuticals, Inc.

Tony Graham, MD (peer review) has no disclosures to report.

Robert Kennedy (planning committee) has no disclosures to report.

Joy Bartnett Leffler, MLA, NASW, CSE (planning committee) has no disclosures to report.

Sandra Haas Binford, MAEd (planning committee) has no disclosures to report.

Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.

Unlabeled Use Disclosure

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

CME Outfitters, LLC, the faculty, and Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC. do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).